文献速递神经肿瘤

miRNA-26a表达与胶质母细胞瘤卡莫司汀缓释片植入疗效相关

miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
PubMed 文献 · Acta Neurochir (Wien) · 2019-09-02

该研究纳入229例胶质母细胞瘤患者,其中80例来自萨尔大学医学中心进行回顾性配对分析(卡莫司汀缓释片组40例、对照组40例),另用TCGA数据库149例独立数据验证。结果显示,卡莫司汀缓释片组中miRNA-26a高表达者的总生存期和无进展生存期显著长于低表达者,也优于对照组;对照组内无此相关性。

要点

  • 卡莫司汀缓释片组中miRNA-26a高表达者预后优于低表达者。
  • 对照组内miRNA-26a表达与生存无显著相关。
  • miRNA-26a有望成为卡莫司汀缓释片治疗反应的预测标志物。

核心结论

  • miRNA-26a表达是胶质母细胞瘤患者接受卡莫司汀缓释片植入治疗反应和临床结局的有前景预测指标。
  • 需要进一步研究以将总体发现转化到患者个体化情境中。

研究设计与样本

  • 回顾性配对分析纳入229例胶质母细胞瘤患者,其中80例来自萨尔大学医学中心,按治疗方案分层为卡莫司汀缓释片组(n=40)和对照组(n=40)。
  • 结果用TCGA数据库149例独立数据集进行验证。
  • 所有肿瘤标本评估miRNA-26a表达、MGMT启动子甲基化和IDH1 R132H突变状态,并与临床数据关联。

主要发现

  • 卡莫司汀缓释片组高表达者总生存期显著长于低表达者(HR 2.750 [95% CI 1.352-5.593];p=0.004)。
  • 卡莫司汀缓释片组高表达者无进展生存期显著长于低表达者(HR 3.091 [95% CI 1.436-6.657];p=0.003)。
  • 卡莫司汀缓释片组17例高表达者较对照组无进展生存期(p=0.013)和总生存期(p=0.007)显著更长。
  • 对照组内未发现上述相关性;TCGA数据集支持这些发现。

临床怎么用

  • 对拟行卡莫司汀缓释片植入的胶质母细胞瘤患者,可检测miRNA-26a表达以辅助预判治疗反应。
  • miRNA-26a高表达者可能从卡莫司汀缓释片植入中获益更多,低表达者需谨慎评估。
  • 目前尚不能将miRNA-26a作为独立决策依据,需结合MGMT启动子甲基化和IDH1状态综合判断。

局限性

  • 主要证据来自单中心回顾性配对分析,样本量有限。
  • 需进一步研究才能在联合治疗背景下评估miRNA-26a的作用并推广至个体化诊疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma multiforme is the most frequent malignant brain tumor in adults being marked with a very poor prognosis. Therapy concept implies concomitant radio-chemotherapy and facultative implantation of carmustine-eluted wafer. Current literature suggests microRNA 26a expression in glioblastoma to interact with alkylating chemotherapy. Subsequently, the aim of this study was to investigate the correlation of miRNA-26a expression and carmustine wafer implantation and its potential usefulness as a predictive marker for therapy response. METHODS: In total, 229 patients with glioblastoma multiforme were included into the final analysis. Of them, 80 cases were recruited from the Saarland University Medical Center for a retrospective matched-pair analysis stratified after therapy regime: One group (carmustine wafer group; n=40) received concomitant radio-chemotherapy with carmustine wafer implantation. The other group (control group; n=40) only received concomitant radio-chemotherapy. The results were confirmed by comparing them with an independent dataset of 149 patients from the TCGA database. All tumor specimens were evaluated for miRNA-26a expression, MGMT promoter methylation, and IDH1 R132H mutation status, and the results were correlated with the clinical data. RESULTS: Twenty-three patients in the carmustine wafer group showed low expression of miRNA-26a, while 17 patients showed a high expression. In the control group, 28 patients showed low expression, while 12 patients showed a high expression. The patients with high miRNA-26a expression in the carmustine wafer group were characterized by a significantly longer overall (hazard ratio [HR] 2.750 [95% CI 1.352-5.593]; p=0.004) and progression-free survival (HR 3.091 [95% CI 1.436-6.657]; p=0.003) than patients with low miRNA-26a expression. The 17 patients in the carmustine wafer group with high miRNA-26a expression showed a significantly longer progression-free survival (p=0.013) and overall survival (p=0.007) compared with the control group. There were no such correlations identified within the control group. TCGA datasets supported these findings. CONCLUSIONS: MiRNA-26a expression turned out to be a promising predictor of therapy response and clinical outcome in glioblastoma patients treated with carmustine wafer implantation. For evaluation of the role of miRNA-26a in a combined therapy setting, further studies are needed in order to translate general findings to the patient's individual situation.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Sippl C, Ketter R, Braun L, et al. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme. Acta Neurochir (Wien). 2019. PMID: 31478117. doi:10.1007/s00701-019-04051-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。